SEC Form 4 · accession 0001562180-19-000564
ARRAY BIOPHARMA INC · ARRY
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Curtis Gale Oltmans
Officer — General Counsel
Period of report
Jan 25, 2019
Accepted (ET)
Jan 29, 2019 · 4:27 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001100412
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Jan 25, 2019 | M | 14,029 | $8.94 | A | 17,950 | D | |
| Common StockF2 | Jan 25, 2019 | S | 14,029 | $18.0001 | D | 3,921 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F3 | $8.94 | Jan 25, 2019 | M | 14,029 | D | — | Aug 15, 2027 | Common Stock | 14,029 | 415,000 | D |
| Stock Option (Right to Buy)F3 | $8.94 | Jan 29, 2019 | M | 11,100 | D | — | Aug 15, 2027 | Common Stock | 11,100 | 403,900 | D |
Explanation of responses
- F1These trades were made pursuant to a Rule 10b5-1 trading plan.
- F2The price reported for these shares is the weighted average sale price of transactions made at prices from $18.00 to $18.001. Details of actual prices for shares sold are available from the Issuer upon request.
- F3The option vests in four equal annual installments beginning August 15, 2018.